Fusion Pharm Stock Fundamentals
| FSPM Stock | USD 0.0001 0.00 0.00% |
Fusion Pharm fundamentals help investors to digest information that contributes to Fusion Pharm's financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharm stock.
At this time, Fusion Pharm's Selling General Administrative is very stable compared to the past year. As of the 25th of November 2024, Total Revenue is likely to grow to about 717.7 K, though Net Loss is likely to grow to (36 K). Fusion | Select Account or Indicator |
Fusion Pharm Company Operating Margin Analysis
Fusion Pharm's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Fusion Pharm Operating Margin | (1.24) % |
Most of Fusion Pharm's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fusion Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Fusion Pharm has an Operating Margin of -1.2414%. This is 96.46% lower than that of the Consumer Staples Distribution & Retail sector and significantly lower than that of the Consumer Staples industry. The operating margin for all United States stocks is 77.47% lower than that of the firm.
Fusion Pharm Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fusion Pharm's current stock value. Our valuation model uses many indicators to compare Fusion Pharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fusion Pharm competition to find correlations between indicators driving Fusion Pharm's intrinsic value. More Info.Fusion Pharm is rated # 3 in return on asset category among its peers. It also is rated # 3 in profit margin category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Fusion Pharm by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fusion Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fusion Pharm's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fusion Pharm could also be used in its relative valuation, which is a method of valuing Fusion Pharm by comparing valuation metrics of similar companies.Fusion Pharm is currently under evaluation in operating margin category among its peers.
Fusion Fundamentals
| Return On Asset | -1.38 | ||||
| Profit Margin | (1.11) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 294.4 K | ||||
| Shares Outstanding | 10.59 M | ||||
| Price To Earning | (0.07) X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 594.4 K | ||||
| Gross Profit | 34.19 K | ||||
| Net Income | (42.08 K) | ||||
| Cash And Equivalents | 1.45 K | ||||
| Total Debt | 1.2 K | ||||
| Current Ratio | 0.73 X | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | 239.84 K | ||||
| Earnings Per Share | (0.15) X | ||||
| Beta | 9.72 | ||||
| Market Capitalization | 1.06 K | ||||
| Total Asset | 4.04 K | ||||
| Retained Earnings | (9.11 K) | ||||
| Working Capital | 728 K | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 459 K | ||||
| Net Asset | 4.04 K |
About Fusion Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 683.6 K | 717.7 K | |
| Cost Of Revenue | 545 K | 572.2 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fusion Pharm Piotroski F Score and Fusion Pharm Altman Z Score analysis. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.